Back to mobile site

China charges former AstraZeneca regional head Leon Wang

February 11, 2026 8:57 AM EST

Syringes with needles are seen in front of a displayed AstraZeneca logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration

Feb 11 (Reuters) - China has ‌officially charged ​AstraZeneca's ​former regional head, Leon Wang, who was detained by authorities in the country more than a year ago ‌in relation to probes into the drugmaker's business.

The company ⁠confirmed Wang's indictment to Reuters on Wednesday, a day after disclosing that Chinese ‌prosecutors had charged a ‌former executive vice president and a former senior employee in November, without naming them.

They were both charged with "unlawful collection of ​personal information, illegal trade and medical insurance fraud," the company said on Tuesday.

AstraZeneca's shares sharply fell after Wang's detention was ⁠announced in October 2024, following probes by China into the company's executives, and alleged ​medical insurance fraud and importation of cancer drugs from Hong Kong.

The stock has recovered since, after signs that ​the impact of the probes could ‌be minor and a series of robust results.

AstraZeneca has also overhauled local leadership in China. It ⁠named a new international executive vice president to replace Wang in December 2024.

The company said last November it had prepaid about $3.5 million in ⁠compensation for the unpaid import taxes, but cautioned that it could face additional ​fines.

AstraZeneca's shares rose as much as 4% to a record high of 147.32 pounds ($201.21) on Wednesday, after the company forecast steady profit growth in 2026.

The ‌company has been investing heavily in China. Last month, it pledged $15 billion in commitments and signed ‌a multi-billion-dollar licensing deal with CSPC for weight loss drugs.

The Financial ⁠Times first reported on ‌Wang's charges.

($1 = 0.7322 pounds)

(Reporting ​by Maggie Fick in London and Raechel Thankam Job in Bengaluru; Writing by Pushkala Aripaka; Editing by ‌Shinjini Ganguli)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters